During our patient safety workshop in San Francisco last March, we examined drug-induced liver injury (DILI), the most frequent reason for safety-related drug withdrawals. We had such a good response that we’ve decided to expand on the topic and include a broader, more global audience.

As part of our “Navigating Global Clinical Trials with your Central Lab” event series, we’ll be presenting a live webinar on October 17^th at 11am ET that discusses the best ways to incorporate and monitor safety parameters in clinical trials based upon early detection of potential organ toxicity.

While DILI tops the list of potential causes for drug candidates being discontinued, kidney and other organ toxicities are also of major concern, because they can have significant and serious impact when discovered in the post-marketing phase. ACM Global’s Head of R&D, Dr. Andrew Botham, our Medical Liaison on the Scientific Affairs team, Dr. Maria-Magdalena Petru and I will discuss the signs of drug-induced organ toxicity (DIOT) and offer proactive strategies for assessing a drug’s adverse effect on vital organs and differentiating true drug-related toxicity versus underlying patient etiologies. 

We’ll also take a look at the latest options for liver and kidney laboratory safety testing, including the importance of testing a combination of novel, early predictive toxicity biomarkers together with conventional tests to reduce the risk of drug induced organ toxicity in clinical trials

Register here for this free, live webinar on October 17^th. We hope you’ll bring your questions and join us for what promises to be an interesting and informative discussion!